Jump to content
PathLabTalk

Malcolm Needs

Premium Members
  • Content Count

    7,718
  • Joined

  • Last visited

  • Days Won

    783
  • Country

    United Kingdom

Malcolm Needs last won the day on October 22

Malcolm Needs had the most liked content!

About Malcolm Needs

  • Rank
    Seasoned poster
  • Birthday 12/14/1954

Profile Information

  • Gender
    Male
  • Interests
    Rugby Union, Cricket, cooking, wine, port, reading, crosswords, lecturing, more wine and more port!
  • Biography
    Pretty boring really, but not that pretty!
  • Location
    Milverton, Somerset, England
  • Occupation
    I have taken a brand new role in the NHSBT and am now involved very much more on the education and training side of red cell immunohaematology. My title is still Reference Service Manager, but with Training after it (Reference Service Manager - Training). I am very excited about this change, as I have a passion for training and education.
    Reference Service Manager with the NHSBT.
    Chartered Scientist.
    Fellow of the British Blood Transfusion Society, having twice served on their National Council.
    Fellow of the Institute of Biomedical Science. Member of their Special Advisory Panel for Transfusion Science and Chief Examiner for Transfusion Science for the Institute.
    Author of the chapter "Human erythrocyte antigens or blood groups" in Fundamentals of Biomedical Science, Transfusion and Transplantation Science, edited by Robin Knight, for the IBMS. 1st edition, Oxford University Press 2013 (ISBN 978-0-19-953328-2, pages 19-44.
    Just been appointed to the BCSH Blood Transfusion Task Force (writing Guidelines).
    Member of ISBT and AABB
    I am now retired from the Blood Service, but still do the other things!
  • Real Name
    Malcolm Needs CSci FIBMS FBBTS

Recent Profile Visitors

14,577 profile views
  1. No, it isn't. In the UK Reference Laboratories, we tended just to screen to see if the antibody reacted at 30oC or not. If it did, as per Petz LD and Garratty G. Immune Hemolytic Anemias, 2nd edition, Churchill-Livingstone, 2004, then it was considered to be clinically significant. We would do nothing else at all. The titre of the antibody was thought to be irrelevant, as it was unusual, although not unique, to find a cold auto-antibody reacting at 30oC (or above) that was not a high titre. We certainly did not spend any time at all determining the specificity of the antibody. As I
  2. We never really worried about the D type of the platelets. The fact is that the transplanted marrow is going to be exposed to the recipient's D Positive red cells for quite some time before the transplanted marrow takes over the production of D Negative red cells, and so the "transplanted immune system" (for want of a better way of putting it) will already have been stimulated to produce an anti-D, if it was going to, by the recipient's own red cells. The number of red cells in a platelet pack, these days, should also be fairly negligible, and the platelets themselves do not express Rh a
  3. Just because an antibody is avid, it does not mean that it is high titre; the two are not identical.
  4. It sounds to me that your lab director is the kind of person who would want to measure the amount of oxygen and carbon dioxide in the air each time someone breathes, AND perform a Change Control at the same time.
  5. I know I'm in the UK, but I can't see how that works. Surely, a thorough revision of a form could make it end up being, in effect, a new form? Would your Medical Director have to approve that?
  6. It depends where you are in the world. I never did in the UK, but I think this is necessary in the USA.
  7. Hopefully, an antibody screen would be performed, and so the anti-H would be detected.
  8. It certainly is if your patient is not a true group O, but is of the rare Oh type. It might just save you killing them!
  9. Patient initial and full surname and hospital number, together with the reagent used (e.g. anti-C, anti-D, anti-Lan, etc). The reagent lot number and expiry date would be recorded elsewhere.
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.